Copyright
©The Author(s) 2017.
World J Gastroenterol. Oct 28, 2017; 23(40): 7265-7273
Published online Oct 28, 2017. doi: 10.3748/wjg.v23.i40.7265
Published online Oct 28, 2017. doi: 10.3748/wjg.v23.i40.7265
Table 1 Adverse events based on type of inflammatory bowel disease and gender n (%)
| Clinical traits | All adverse events | Infusion reactions | Allergic reactions | Lupus-like reactions | Rash | Other |
| Type of IBD | ||||||
| Crohn's disease (n = 954) | 220 (23) | 52 (5) | 45 (5) | 14 (1) | 40 (4) | 69 (7) |
| Ulcerative colitis (n = 260) | 42 (16) | 14 (5) | 4 (2) | 4 (2) | 10 (4) | 10 (4) |
| IBDU (n = 44) | 7 (16) | 0 (0) | 0 (0) | 1 (2) | 2 (5) | 4 (9) |
| Total | 269 (21) | 66 (5) | 49 (4) | 19 (1.5) | 52 (4) | 83 (7) |
| Gender | ||||||
| Male (n = 624) | 108 (17) | 28 (4) | 24 (4) | 3 (0.5) | 17 (3) | 36 (6) |
| Female (n = 634) | 161 (25) | 38 (6) | 25 (4) | 16 (3) | 35 (6) | 47 (7) |
- Citation: Lew D, Yoon SM, Yan X, Robbins L, Haritunians T, Liu Z, Li D, McGovern DP. Genetic associations with adverse events from anti-tumor necrosis factor therapy in inflammatory bowel disease patients. World J Gastroenterol 2017; 23(40): 7265-7273
- URL: https://www.wjgnet.com/1007-9327/full/v23/i40/7265.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i40.7265